Acne vulgaris is a chronic inflammatory skin disease affecting the hair follicles and sebaceous glands, commonly seen in adolescents. The need for advanced therapies is driving innovation, with a growing focus on non-antibiotic and hormone-based treatments. Recent developments include topical retinoids, androgen receptor inhibitors, and immunomodulators. Acne vulgaris pipeline analysis by Expert Market Research highlights promising candidates like clascoterone, trifarotene, and sarecycline that are undergoing clinical development. With rising skin care awareness, improved formulations, and expanding clinical trials, the acne vulgaris therapeutics market is poised for strong growth in the coming years.
Major companies involved in the acne vulgaris pipeline analysis include Dermata Therapeutics, Pfizer, and others.
Leading drugs currently in the pipeline include DMT310, ASC40, and others.
The rising demand for antibiotic-free treatments, increased research in retinoid and hormonal therapies, and growing awareness of long-term skin health are driving the acne vulgaris pipeline growth.
The Acne Vulgaris Pipeline Analysis Report by Expert Market Research gives comprehensive insights into acne vulgaris therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for acne vulgaris. The acne vulgaris report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The acne vulgaris pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with acne vulgaris treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical study, phase type, drug type, route of administration, and ongoing product development activities related to acne vulgaris.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Acne vulgaris is a common chronic skin condition that occurs when hair follicles become clogged with oil and dead skin cells. It often leads to whiteheads, blackheads, pimples, or cysts, primarily on the face, chest, and back. Hormonal changes, excess sebum production, bacterial growth, and inflammation contribute to its development, particularly during adolescence.
Acne vulgaris treatment includes topical or oral antibiotics, retinoids, benzoyl peroxide, and hormonal therapies to reduce inflammation, clear pores, and prevent new breakouts. For instance, in October 2023, the U.S. Food and Drug Administration approved CABTREO, a fixed-dose triple-combination topical gel for acne vulgaris, offering once-daily treatment with proven efficacy and simplified dosing.
Acne vulgaris has a global prevalence of 20.5%, affecting 1 in 5 individuals. Epidemiological data show the highest incidence in adolescents and young adults at 28.3%, followed by adults aged 25 to 39 at 19.3%. Women are affected more at 23.6% compared to men at 17.5%. Regional prevalence is highest in Latin America at 23.9% and East Asia at 20.2%, highlighting the need for targeted dermatological interventions.
This section of the report covers the analysis of acne vulgaris drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III accounts for 39.22% of the acne vulgaris drug pipeline, highlighting significant late-stage clinical activity. Phase II follows with 31.37%, indicating a strong mid-stage pipeline. Phase IV represents 11.76%, showing continued post-marketing research. Phase I covers 11.76%, and Early Phase I holds 5.88%. This balanced progression supports future innovation and market growth in the acne vulgaris treatment landscape.
The drug molecule categories covered under the acne vulgaris pipeline analysis include small molecules, biologics, hormonal agents, RNA-based therapies, nanoparticle/formulation-based molecules, and others. The acne vulgaris report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for acne vulgaris.
Vaccine-based immunotherapies are emerging as novel drug classes in the acne vulgaris treatment pipeline. For example, Sanofi’s acquisition of Origimm Biotechnology introduced ORI-001, a recombinant protein-based therapeutic vaccine candidate. It targets Cutibacterium acne and aims to modulate the immune response. Sanofi also plans to utilize its mRNA platform to advance the candidate into early-phase clinical trials.
The EMR report for the acne vulgaris pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed acne vulgaris therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in acne vulgaris clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for acne vulgaris. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of acne vulgaris drug candidates.
DMT310-009, sponsored by Dermata Therapeutics, is currently undergoing a Phase III clinical trial to evaluate its tolerability, safety, and efficacy in patients with moderate to severe acne vulgaris. DMT310 (branded as XYNGARI) is a once-weekly topical treatment derived from a freshwater sponge, utilizing mechanical exfoliation and bioactive compounds with antimicrobial and anti-inflammatory properties.
ASC40, developed by Ascletis Pharmaceuticals Co., Ltd., is being evaluated in a Phase III extension trial to assess its long-term safety in patients with moderate to severe acne vulgaris. The study is enrolling patients from a prior trial and is administering ASC40 (Denifanstat), a selective oral FASN inhibitor. It targets reduced sebum production and inflammation.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Acne Vulgaris Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for acne vulgaris. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within acne vulgaris pipeline insights.
Global Severe Acne Vulgaris Treatment Market Report
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share